Fujirebio joins the Global Health Innovative Technology (GHIT) Fund

The GHIT Fund is a Japan-based international public-private partnership fund (PPP) that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund facilitates collaboration between research organizations in Japan and overseas to accelerate the development of new drugs, in-vitro diagnostics testing solutions, and vaccines for neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases in developing and emerging countries.

“By participating in the fund, Fujirebio will leverage its R&D efforts in the fight against infectious diseases around the world,” stated Goki Ishikawa, President & CEO, Fujirebio Holdings, Inc. “Fujirebio remains strongly committed to a further contribution to addressing global health issues such as improvement of access to healthcare through this participation in the GHIT Fund.”

Fujirebio has joined the GHIT Fund as an Associate Partner.